Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

Haematologica

Volumn 96, Issue 10, 2011, Pages 1568-1570

  Sockel, Katja ^a   Wermke, Martin ^a   Radke, Jörgen ^a   Kiani, Alexander ^b   Schaich, Markus ^a   Bornhäuser, Martin ^a   Ehninger, Gerhard ^a   Thiede, Christian ^a   Platzbecker, Uwe ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

AML; Azacitidine; MRD; NPM1; Nucleophosmin

Indexed keywords

AZACITIDINE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; GENE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KARYOTYPE; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NPM1 GENE; THROMBOCYTOPENIA;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; RECURRENCE; TREATMENT OUTCOME;

EID: 80053649326     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.044388     Document Type: Letter

References (10)

1. Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20(6):1103-1108.
2. Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol. 2010;22(6): 656-663.
3. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kröger N. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem celltransplan tation. Exp Hematol. 2009;37(1):135-142.
4. Shayegi N, Bornhäuser M, Schaich M, Schetelig J, Kramer M, Platzbecker U, et al. Quantitative monitoring of mutated NPM1 enables early detection of impending relapse in patients with acute myeloid leukemia following conventional chemotherapy and allogeneic stem cell transplantation. Bone marrow transplantation (EBMT Annual Meeting Abstracts). 2011. abstract 1158.
5. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114(11):2220-2231.
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
7. Wermke M, Thiede C, Kiani A, Ehninger G, Bornhäuser M and Platzbecker U. Successful treatment of molecular relapse in NPM1- positive AML using 5-azacytidine. Leukemia. 2010;24(1):236-237.
8. de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116(23):5420-5431.
9. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116(11):1908-1918.
10. Hokland P, Ommen HB. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood. 2011;117(9): 2577-2584.